Treatment of Hepatocellular Carcinoma with Portal Vein Thrombosis by Sorafenib Combined with Hepatic Arterial Infusion Chemotherapy
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Treatment with sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced hepatocellular carcinoma. Although the effects of combining sorafenib therapy with other anticancer treatment modalities have not been clarified, combination treatment is strongly expected to be beneficial. We report the case of a 50-year-old man who exhibited a partial response and portal vein thrombosis (PVT) revascularization after sorafenib combined with hepatic arterial infusion chemotherapy (HAIC). He exhibited a decrease in tumor size and PVT after 2 months of sorafenib monotherapy. However, no additional response was seen during the subsequent 2 months. To achieve a better tumor response, we combined HAIC with sorafenib. Daily cisplatin (7 mg/m2 on days 1-5) and 5-fluorouracil (170 mg/m2 on days 1-5) were infused repeatedly every 4 weeks, and the sorafenib prescription was modified. After four cycles of combined therapy, both the tumor size and PVT were much improved and exhibited partial response.
Abstract
Treatment with sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced hepatocellular carcinoma. Although the effects of combining sorafenib therapy with other anticancer treatment modalities have not been clarified, combination treatment is strongly expected to be beneficial. We report the case of a 50-year-old man who exhibited a partial response and portal vein thrombosis (PVT) revascularization after sorafenib combined with hepatic arterial infusion chemotherapy (HAIC). He exhibited a decrease in tumor size and PVT after 2 months of sorafenib monotherapy. However, no additional response was seen during the subsequent 2 months. To achieve a better tumor response, we combined HAIC with sorafenib. Daily cisplatin (7 mg/m2 on days 1-5) and 5-fluorouracil (170 mg/m2 on days 1-5) were infused repeatedly every 4 weeks, and the sorafenib prescription was modified. After four cycles of combined therapy, both the tumor size and PVT were much improved and exhibited partial response.
참고문헌 (22)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Llovet JM, "Hepatocellular carcinoma", Lancet, 362, pp.1907~1917 (2003)
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
- Lopez PM, "Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials", Aliment Pharmacol Ther, 23, pp.1535~1547 (2006)
- Minagawa M, "Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus", World J Gastroenterol, 12, pp.7561~7567 (2006)
- Okuda K, "Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients", Cancer, 56, pp.918~928 (1985)
- Yeung YP, "Natural history of untreated nonsurgical hepatocellular carcinoma", Am J Gastroenterol, 100, pp.1995~2004 (2005)
- Asahara T, "Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculatures", Hepatogastroenterology, 46, pp.1862~1869 (1999)
- Tanaka A, "Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein", Hepatogastroenterology, 43, pp.637~643 (1996)
- Yamaoka Y, "Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein", World J Surg, 16, pp.1172~1177 (1992)
- Furuse J, "Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal sh", Radiology, 204, pp.787~790 (1997)
- Yen FS, "Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis", J Gastroenterol Hepatol, 10, pp.237~240 (1995)
- Ando E, "A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein", Cancer, 79(`), pp.1880~1896 (1997)
- Iwamiya T, "Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system", Cancer Chemother Pharmacol, 33(Suppl), pp.S134~S138 (1994)
- Chen SC, "The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma", Cancer Chemother Pharmacol, 33(Suppl), pp.S124~S127 (1994)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- "BMC Cancer", 2008, 349~
- Plastaras JP, "Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation", Cancer Res, 67, pp.9443~9454 (2007)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Novi M, "Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma", Am J Gastroenterol, 104, pp.1852~1854 (2009)
- Li Q, "Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma", J Exp Clin Cancer Res, 25, pp.403~409 (2006)